Hypercalcemia Treatment Market Analysis | Coherent Market Insights

1. Coherent Market InsightS Market Research and Business Consulting Services https://www.coherentmarketinsights.com/ COVID-19 Impact Tracker

2. Hypercalcemia Treatment Market Analysis (2020-2027) • Hypercalcemia is characterized by increased level of calcium in the blood. The condition can be life-threatening and is associated with neoplastic diseases. Hypocalcemic drugs are used for the treatment of hypercalcemia. • The global hypercalcemia treatment market is estimated to account for US$ 10,696.6 Mn in terms of value in 2018 and is expected to reach US$ 28,060.0 Mn by the end of 2028.

3. Global Hypercalcemia Treatment Market: Drivers • High incidence of hypercalcemia is a major factor boosting growth of the global hypercalcemia treatment market. For instance, in the study, ‘Incidence of hypocalcemia and hypercalcemia in hospitalized patients: Is it changing?’, published in the Journal of Clinical and Translational Endocrinology, in September 2018, researchers found that 27.72% of the study patients suffered from hypocalcemia and 4.74% from hypercalcemia. Moreover, 585 cases of hypercalcemia were detected. • Moreover, increasing prevalence of cancer is also expected to aid in growth of the market. For instance, according to the World Health Organization, around 18.1 million new cases and 9.6 million deaths were registered due to cancer worldwide in 2018.

4. s Moreover, favorable reimbursement scenario is also expected to aid in growth of the market. Reimbursements enable lesser out-of-pocket costs of treatment for patients, despite having a low income eligibility. For instance, Amgen has a reimbursement policy on its XGEVA (denosumab injection), in which the company pays the out-of-pocket amount in excess of US$ 25 per dose; up to US$ 10,000 in assistance per calendar year. Approximately 70% of XGEVA patients with commercial or Medicare coverage incurred US$ 0 out-of-pocket cost due to favorable reimbursement policy offered by Amgen, Inc. North America region held dominant position in the global hypercalcemia treatment market in 2018, accounting for 45.5% share in terms of value, followed by Europe.

5. Global Hypercalcemia Treatment Market: Restraints • Companies face challenges with regard to locating patients for clinical trials and logistics issues related to institutes conducting trials. Such factors increase the costs incurred in R&D of hypercalcemia treatment, which is expected to hinder growth of the global hypercalcemia treatment market. • Moreover, it is challenging to distinguishing primary hyperparathyroidism from conditions that will not respond to parathyroidectomy, which is also expected to limit growth of the market.

6. Global Hypercalcemia Treatment Market: Opportunities • Product innovations in hypercalcemia drug types other than bisphosphonates is expected to offer lucrative growth opportunities for players in the global hypercalcemia treatment market. Bisphosphonate is the single largest product being utilized for hypercalcemia treatment. End users have recognized the bisphosphonate therapy as effective. Still, the global hypercalcemia treatment market is yet to witness major product innovations in the product types of calcitonin, calcimimetics, and glucocorticoids.

7. d • Improving systems for recognizing hypercalcemia can aid in addressing common causes for delayed diagnosis and treatment of the disease, thereby aiding in growth of the market. Educating patients and providers about the consequences of untreated disease can also help in this regard.

8. d • Bisphosphonates segment in the global hypercalcemia treatment market was valued at US$ 7,306.2 Mn in 2018 and is expected to reach US$ 19,798.3 Mn by 2027 at a CAGR of 11.7% during the forecast period.

9. Market Trends/Key Takeaways • AfricaR&Din the treatment of hypercalcemia is augmenting growth of the market. For instance, in July 2019, researchers from AscendisPharma A/S, in their study, ‘Design and Preclinical Development of TransCon PTH, an Investigational Sustained?Release PTH Replacement Therapy for Hypoparathyroidism,’ reported that TransCon PTH can be used to normalize blood levels of calcium and phosphate. • Sarcoidosis, a complex disease with no known cause, is linked with hypercalcemia. The study, “Hypercalcemic pancreatitis a rare presentation of sarcoidosis: A case report,” published in the journal Medicine in January 2018, reported a sarcoidosis patient with pancreatitis — inflammation of the pancreas — and hypercalcemia.

10. d

11. Global Hypercalcemia Treatment Market: Competitive Landscape • Major players operating in the global hypercalcemia treatment market include, Bayer Pharma AG, Sun Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., Amgen Inc., Novartis AG, Dr. Reddy’s Laboratories Ltd., Cipla Inc., and XOMA Corporation.

12. Global Hypercalcemia Treatment Market: Key Developments  • Players in the market are focused on attending various conferences to expand their customer base. For instance, in October 2019, XOMA Corporation presented at the 2019 Cantor Fitzgerald Global Healthcare Conference held in New York.

13. Request sample copy here Request PDF brochure here Request Customization here Talk to Analyst Buy Now Reference: https://www.coherentmarketinsights.com/market-insight/hypercalcemia-treatment-market-3504

14. About Us: • Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. • What we provide: • Customized Market Research Services • Industry Analysis Services • Business Consulting Services • Market Intelligence Services • Long term Engagement Model • Country Specific Analysis

15. Contact Us: • Mr. Shah • Coherent Market Insights Pvt. Ltd. • Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S. • Phone: +1-206-701-6702 • Email :sales@coherentmarketinsights.com

16. Thank You! Kindly follow CMI Social Media Profiles for the latest company updates Facebook Linkedin Twitter https://www.coherentmarketinsights.com/